explore -WSS

explore

author：focus 2025-10-01 22:58:22 - browse：81

Transparent plastic divider on the reception desk in the hospital admission department with red lettering emergency. — Adobe

QuidelOrtho has recalled nearly 8,000 potentially faulty blood tests meant to help doctors quickly determine whether a patient is having a heart attack.

The tests inaccurately showed low levels of troponin, a protein that indicates damage to the heart. A false negative could lead doctors to mistakenly conclude their patient is not having a heart attack, delaying diagnosis or treatment when time is of the essence.

The device maker, which also sells products like the QuickVue Covid-19 antigen test, sent letters to health systems in May telling them to immediately stop using the test. The Food and Drug Administration classified the recall as serious, because problems with the product could result in serious injury or death. QuidelOrtho has reported 41 complaints, but no injuries or deaths so far.

The tests, which use either a blood or plasma sample, promise to return results in under half an hour. They are used in emergency rooms to triage patients suspected of having a heart attack.

Related: With Wegovy and Ozempic’s success, can device makers keep up in the race to treat obesity?

The FDA said the patients most at risk are those with zero or abnormal heart attack symptoms, for whom a diagnosis would be easy to miss without an accurate lab test.

The company advised using a different testing method to detect heart attacks. If none are available, doctors should be extra wary of the blood panel’s readings, perform multiple tests to confirm low troponin levels, and also reference data from EKGs and other imaging.

San Diego-based QuidelOrtho said the error is due to a “raw material issue” in its recall record. The issue caused the test to falsely pick up 30% less troponin than is present. The company did not respond to STAT’s request for more information on the error.

The test maker’s last serious recall was in 2021 for reports of false negatives from its Lyra PCR Covid-19 test when used with certain lab equipment. The notice impacted more than 18,000 test kits.

Previous article： Supreme Court strikes down use of affirmative action
Next article： Covid’s new normal has set in amid another rise in cases

WSS

Neurocrine congenital adrenal hyperplasia trial succeeds

Free Covid tests will again be offered to all U.S. households

The unintended consequences of overturning Roe v. Wade

Key Senate panel to consider PBM, drug pricing reform package

PBMs drew scrutiny in House hearing — and so did pharma

David Liu startup to focus on CRISPR delivery

hotspot

explore

Related: With Wegovy and Ozempic’s success, can device makers keep up in the race to treat obesity?

entertainment

As demand for Covid shots wanes, Moderna seeks its next success

Information blocking fines are now fair game in health care

In Memoriam: Notable people who died in 2023

DeepMind touts AlphaFold's new skills as protein folding AI models face off

ChatGPT in medicine: STAT answers readers' burning questions

FDA weighs limits of animal data in assessing artificial wombs

United colonoscopy coverage change 'may cost lives,' doctors say

Inari Medical to buy amputation prevention company LimFlow

Novavax promises a turnaround & Lilly roils the obesity market

Travis Kelce and the trap of celebrity vaccine endorsements

focus

The health care issue Democrats can’t solve: hospital reform

Covid’s new normal has set in amid another rise in cases

White House Covid adviser calls on docs to combat misinformation

Key Senate panel to consider PBM, drug pricing reform package

People with substance use disorder deserve online privacy

FDA weighs limits of animal data in assessing artificial wombs

knowledge

knowledge

hotspot

knowledge